<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354445</url>
  </required_header>
  <id_info>
    <org_study_id>EOP1023</org_study_id>
    <nct_id>NCT00354445</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD</brief_title>
  <official_title>A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyetech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eyetech Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety and efficacy of Macugen given as
      maintenance therapy in patients who have had initial success with another AMD treatment.
      Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>1000</enrollment>
  <condition>Age-Related Macular Degeneration (AMD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaptanib sodium (Macugen)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subfoveal CNV secondary to AMD

          -  At least 1 but not more than 3 prior treatments for AMD

        Exclusion Criteria:

          -  Subfoveal scar or subfoveal atrophy

          -  Significant media opacities, including cataract, which might interfere with visual
             acuity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Macugen Information</last_name>
    <phone>1-866-622-8436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Retina Research Institute of Texas, LLC</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macugen Information</last_name>
      <phone>866-622-8436</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>January 12, 2007</last_update_submitted>
  <last_update_submitted_qc>January 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2007</last_update_posted>
  <keyword>Age-Related Macular Degeneration (AMD)</keyword>
  <keyword>pegaptanib sodium</keyword>
  <keyword>subfoveal CNV</keyword>
  <keyword>macugen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

